42 results
DEFM14A
HARP
Harpoon Therapeutics Inc
8 Feb 24
Proxy related to merger
7:00am
plans and operations or affect our ability to retain or recruit key employees;
the response of our competitors to the proposed Merger;
the amount
PREM14A
HARP
Harpoon Therapeutics Inc
29 Jan 24
Preliminary proxy related to merger
4:52pm
that the proposed Merger may disrupt our current plans and operations or affect our ability to retain or recruit key employees;
the response of our
DFAN14A
HARP
Harpoon Therapeutics Inc
8 Jan 24
Additional proxy materials by non-management
5:15pm
that is designed to recruit a patient’s own immune cells to kill tumor cells. HPN328 is being evaluated as monotherapy and in combination in an ongoing
DEFA14A
HARP
Harpoon Therapeutics Inc
8 Jan 24
Additional proxy soliciting materials
8:04am
to recruit a patient’s own immune cells to kill tumor cells. HPN328 is being evaluated as monotherapy and in combination in an ongoing open-label
8-K
EX-99.2
HARP
Harpoon Therapeutics Inc
8 Jan 24
Entry into a Material Definitive Agreement
8:01am
cell Activating Construct (TriTAC®) platform that is designed to recruit a patient’s own immune cells to kill tumor cells. HPN328 is being evaluated
8-K
EX-99.1
c3ag40tyaa7l42yk
12 Dec 22
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
4:03pm
8-K
EX-99.2
h4i6yo
13 Dec 21
Other Events
5:28pm
8-K
EX-99.1
y8ef44s5kjyxj7amqqq
13 Dec 21
Other Events
5:28pm
8-K
EX-99.1
0ye4td t9gg
4 Jun 21
Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting
4:40pm
8-K
EX-99.2
u9rwvx323j45l g210f
4 Jun 21
Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting
4:40pm